Recent News

• 12.11.2025 - Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
• 12.09.2025 - Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
• 12.02.2025 - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 11.20.2025 - Opus Genetics to Participate in Upcoming Investment Conferences
• 11.13.2025 - Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
• 11.12.2025 - Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
• 11.06.2025 - Opus Genetics Announces $23 Million Registered Direct Offering
• 11.06.2025 - Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
• 11.04.2025 - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 11.03.2025 - Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness

Recent Filings

• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 8-K Current report
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.06.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 4/A Statement of changes in beneficial ownership of securities
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities